HIV Unit Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara, Calle Hospital 278, Colonia Alcalde Barranquitas, Guadalajara, Jalisco, 44280, Mexico.
Nutr J. 2012 Oct 29;11:90. doi: 10.1186/1475-2891-11-90.
HIV-infection results in damage and dysfunction of the gastrointestinal system. HIV enteropathy includes pronounced CD4+ T-cell loss, increased intestinal permeability, and microbial translocation that promotes systemic immune activation, which is implicated in disease progression. A synbiotic is the combination of probiotics and prebiotics that could improve gut barrier function. Our study goal was to determine whether the use of a synbiotic, probiotics or a prebiotic can recover immunological parameters in HIV-infected subjects through of a reduction of microbial translocation and pro-inflammatory cytokine production.
A randomized, double-blind controlled study was performed; twenty Antiretroviral treatment-naïve HIV-infected subjects were subgrouped and assigned to receive a synbiotic, probiotics, a prebiotic, or a placebo throughout 16 weeks.
We had no reports of serious adverse-events. From baseline to week 16, the synbiotic group showed a reduction in bacterial DNA concentrations in plasma (p = 0.048). Moreover, the probiotic and synbiotic groups demonstrated a decrease in total bacterial load in feces (p = 0.05). The probiotic group exhibited a significant increment of beneficial bacteria load (such as Bifidobacterium; p = 0.05) and a decrease in harmful bacteria load (such as Clostridium; p = 0.063). In the synbiotic group, the CD4+ T-cells count increased (median: +102 cells/μL; p = 0.05) and the level of Interleukin 6 cytokine decreased significantly (p = 0.016).
Our study showed a significant increase in CD4+ T lymphocyte levels in the synbiotic group, which could delay the initiation of antiretroviral therapy and decrease costs in countries with limited resources.
HIV 感染会导致胃肠道系统受损和功能障碍。HIV 肠病包括明显的 CD4+T 细胞丧失、肠道通透性增加和微生物易位，从而促进全身免疫激活，这与疾病进展有关。共生元是益生菌和益生元的组合，可改善肠道屏障功能。我们的研究目的是确定使用共生元、益生菌或益生元是否可以通过减少微生物易位和促炎细胞因子的产生来恢复 HIV 感染受试者的免疫参数。
进行了一项随机、双盲对照研究；将 20 名未接受抗逆转录病毒治疗的 HIV 感染受试者分组，并在 16 周内分别接受共生元、益生菌、益生元或安慰剂治疗。
我们没有报告严重不良事件。从基线到第 16 周，共生元组血浆中细菌 DNA 浓度降低（p = 0.048）。此外，益生菌和共生元组粪便中总细菌负荷减少（p = 0.05）。益生菌组有益细菌（如双歧杆菌）负荷显著增加（p = 0.05），有害细菌（如梭状芽孢杆菌）负荷减少（p = 0.063）。在共生元组中，CD4+T 细胞计数增加（中位数：+102 个/μL；p = 0.05），白细胞介素 6 细胞因子水平显著降低（p = 0.016）。
我们的研究表明，共生元组 CD4+T 淋巴细胞水平显著增加，这可能延迟在资源有限的国家启动抗逆转录病毒治疗并降低成本。
